REPORT HIGHLIGHT
The hemophilia market is estimated to represent a global market of USD 11.62 billion by 2019 with growth rate of 5.3%.

Market Dynamics

Over the eight years to 2016, revenue for the hemophilia industry is anticipated trend higher. Increasing neonatal population is expected to drive the hemophilia diagnosis demand globally. The World Population Meter stated that more than 88.0 billion newborns were reported in 2015 resulting in about 250 births per minute. Of which, approximately 2.8 million infants died within the first month, due to lack of skilled care and proper screening of the babies. The World Health Organization (WHO) also stated that around 2.6 million children died in their first month of life across the globe, which is 7,000 newborn deaths every day. In addition, strong product pipeline will further stimulate the industry growth to great extent over the future period. For example, N9-GP, Concizumab, N8-GP, and Recombinant factor VIIa are some of the bleeding disorder therapeutics under clinical investigations by Novo Nordisk. Despite the industry pipeline increasing, some potential threats exist which will likely to hinder growth prospects going forward. Factors such as high treatment cost coupled with low acceptance of advanced technologies are posing a potential threat to the market.

Types Takeaway

In terms of types, the market is categorized into A, B, C, and other types. Type A accounted for the highest share of the total market. In 2019, the segment recorded 6.8 billion and is expected to dominate the global market over the forecast period. This type is acquired due to the deficiency of clotting factor VIII, which is an anti-hemophilic factor (AHF). According to the National Hemophilia Foundation (NHF), 1 in 5,000 male population affect with type A disorder, which makes it four times more common compared to the type B. As per the Hemophilia News Today, around 4,000 to 5,000 males are affected with type A disease worldwide. Markets besides hemophilia A, B & C is expected to generate the remaining 5.0% of market revenue in 2019.

COVID 19 Impact on hemophilia market
As key companies move from reacting to mitigating the impact of the COVID-19 outbreak, they are keenly focusing on strategies that may result in emerging as strong market player. The published research included the detailed study related to the COVID-19 impact on the supply chain based on both downstream and upstream markets. The proposed report also includes the future development in the hemophilia Market in relation with the impact of COVID-19 on the market.
Key Vendor Takeaway

Companies namely, Novo Nordisk, Bayer AG, Pfizer, Inc., Baxalta, and Biogen are profiled. In light of more players entering in this market. the degree of competition has intensified over a couple of years. Competition is based on the development of new therapeutics and co-pay programs.

For example, Grifols provide co-pay programs such as ALPHANATE Copay Program and AlphaNine SD Copay card for this bleeding disorder treatment with an unlimited monetary limit. In addition, companies are engaged in donation activities with government organizations. For instance, in 2016, the World Federation of Hemophilia collected 1.5 million units of anti-hemophilic agents from CSL Behring as a donation on World Hemophilia Day.

The market size and forecast for each segment has been provided for the period 2016 to 2027, considering 2019 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2021 to 2027 for every reported segment.

The years considered for the study are:

Historical Year – 2016 to 2018
Base Year – 2019
Estimated Year – 2020
Projected Year – 2027

The proposed reports analyse and evaluates the COVID-19 impact, and anticipated change on the future market scenario on this industry, by taking into the account the economic, political, technological, and social, parameters.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

HEMOPHILIA MARKET, BY TYPES

Hemophilia A
Hemophilia B
Hemophilia C
Others

HEMOPHILIA MARKET, BY TREATMENT
On-demand
Prophylaxis

HEMOPHILIA MARKET, BY THERAPY
Immune Tolerance Induction (ITI) therapy
Replacement therapy
Gene therapy

HEMOPHILIA MARKET, BY REGION
North America
U.S.
Canada
Europe
Germany
France
Rest of Europe
Asia Pacific
India
China
Rest of APAC
Rest of the World
Middle East and Africa
Latin America